DUBLIN, June 3, 2022 /PRNewswire/ — The “Lymphedema Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment Type, By Affected Area, By End User, By Region; Segment Forecast, 2022-2030” report has been added to from ResearchAndMarkets.com offer.

The global lymphedema treatment market size is expected to reach $1,735.36 million by 2030 according to a new study. The report provides a detailed overview of current market dynamics and provides analysis of future market growth.

The increasing number of people affected by lymphedema is expected to drive the growth of the lymphedema cure industry. Additionally, with the increasing prevalence of the disease, innovative and advanced treatments are being developed to minimize the risks during recovery. Additionally, increasing healthcare expenditures coupled with growing innovation in the healthcare sector is expected to further boost the growth of the industry. Additionally, the launch of new medical devices by pharmaceutical companies is also fueling the growth of the industry across the globe.

On the basis of type, the Secondary Lymphedema segment is dominating the global industry and is expected to lead the industry during the forecast period. Secondary lymphedema is usually caused by damage to the lymphatic system from cancer treatment with radiation therapy and surgery, among other things. According to the CDC (Centers for Disease Control & Prevention), the majority of patients suffer from secondary lymphedema. Thus, the presence of a large pool of patients is expected to drive the growth of the segment.

Growing investment by government and private pharmaceutical companies in R&D for drug discovery is expected to present huge growth opportunities for the industry. Additionally, the rising prevalence of cancer and other chronic diseases is expected to drive the growth of the industry. For example, according to the International Agency for Research on Cancer (IARC), in 2018 nearly 17.0 million new cancer cases were recorded, which is expected to reach 27.5 million new cancer cases by 2040 due to population growth and aging. population. Thus, the growing frequency of cancer further acts as a catalyzing factor for the growth of the market.

Market players such as Avet Pharmaceuticals Inc., AIROS Medical Inc., Bio-compression Systems, Cardinal Health, Essity (BSN medical GmbH), Convatec Inc., Huntleigh Healthcare Limited, Koya Medical, JUZO, Medi GmbH, Lohmann & Rauscher , Mego Afek Ltd., PAUL HARTMANNSmith+Nephew HERANTIS PHARMA Plc, SIGVARIS GROUP, Tactile medical and ThermoTek are some of the major players operating in the global market.

Moreover, companies are launching collaborative initiatives in order to increase their market share. For example, in August 2021AIROS Medical, announced an exclusive distribution agreement in the United States for the fist assist fa-1 compression devices, allowing the company to strengthen its presence in the market.

Main topics covered:

1. Introduction

2. Executive Summary

3. Research methodology

4. Global Lymphedema Treatment Market Overview
4.1. Lymphedema Treatment – Industry Overview
4.2. Lymphedema Treatment Market Dynamics
4.2.1. Drivers and opportunities Prevalence of lymphedema and cancer Technological Advances in Diagnostic Imaging Modalities
4.2.2. Constraints and challenges Short half-life of radiopharmaceuticals
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining power of suppliers (moderate)
4.3.2. Threats from new entrants: (low)
4.3.3. Bargaining power of buyers (moderate)
4.3.4. Substitute Threat (Moderate)
4.3.5. Rivalry between existing companies (high)
4.4. PESTEL analysis
4.5. Lymphedema Treatment Market Trends
4.6. Value chain analysis
4.7. COVID-19 Impact Analysis

5. Global Lymphedema Treatment Market, By Treatment Type
5.1. Main conclusions
5.2. Introduction
5.2.1. Global Lymphedema Treatment Market, by Treatment Type, 2018-2030 (USD Million)
5.3. Compression therapy
5.3.1. Global Lymphedema Treatment Market, by Compression Therapy, by Region, 2018-2030 (USD Million)
5.4. Operation
5.4.1. Global Lymphedema Treatment Market, by Surgery, by Region, 2018-2030 (USD Million)
5.5. Drug therapy
5.5.1. Global Lymphedema Treatment Market, by Drug Therapy, by Region, 2018-2030 (USD Million)
5.6. Laser therapy
5.6.1. Global Lymphedema Treatment Market, by Laser Therapy, by Region, 2018-2030 (USD Million)
5.7. Others
5.7.1. Global Lymphedema Treatment Market, By Others, By Region, 2018-2030 (USD Million)

6. Global Lymphedema Treatment Market, By Affected Area
6.1. Main conclusions
6.2. Introduction
6.2.1. Global lymphedema treatment market, by affected area, 2018-2030 (USD million)
6.3. Inferior member
6.3.1. Global Lymphedema Treatment Market, by Lower Limb, by Region, 2018-2030 (USD Million)
6.4. Upper limb
6.4.1. Global Lymphedema Treatment Market, by Upper Limb, by Region, 2018-2030 (USD Million)
6.5. Genitals
6.5.1. Global Lymphedema Treatment Market, by Genitals, by Region, 2018-2030 (USD Million)

7. Global Lymphedema Treatment Market, By End Use
7.1. Main findings
7.2. Introduction
7.2.1. Global Lymphedema Treatment Market, By End Use, 2018-2030 (USD Million)
7.3. Hospital
7.3.1. Global Lymphedema Treatment Market, By Hospital, By Region, 2018-2030 (USD Million)
7.4. Specialized clinics
7.4.1. Global Lymphedema Treatment Market, by Specialty Clinics, by Region, 2018-2030 (USD Million)
7.5. Specialized clinics
7.5.1. Global Lymphedema Treatment Market, by Specialty Clinics, by Region, 2018-2030 (USD Million)
7.6. Others
7.6.1. Global Lymphedema Treatment Market, By Others, By Region, 2018-2030 (USD Million)

8. Global Lymphedema Treatment Market, By Geography

9. Competitive Landscape
9.1. Expansion and acquisition analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles
10.1. AIROS Medical Inc.
10.1.1. Company presentation
10.1.2. Financial performance
10.1.3. Product Benchmarking
10.1.4. Recent development
10.2. Avet Pharmaceuticals Inc.
10.2.1. Company presentation
10.2.2. Financial performance
10.2.3. Product Benchmarking
10.2.4. Recent development
10.3. Biocompression systems
10.3.1. Company presentation
10.3.2. Financial performance
10.3.3. Product Benchmarking
10.3.4. Recent development
10.4. Cardinal Health
10.4.1. Company presentation
10.4.2. Financial performance
10.4.3. Product Benchmarking
10.4.4. Recent development
10.5. Convatec inc.
10.5.1. Company presentation
10.5.2. Financial performance
10.5.3. Product Benchmarking
10.5.4. Recent development
10.6. Essity (BSN medical GmbH)
10.6.1. Company presentation
10.6.2. Financial performance
10.6.3. Product Benchmarking
10.6.4. Recent development
10.7. Huntleigh Healthcare Limited
10.7.1. Company presentation
10.7.2. Financial performance
10.7.3. Product Benchmarking
10.7.4. Recent development
10.8. JUZO
10.8.1. Company presentation
10.8.2. Financial performance
10.8.3. Product Benchmarking
10.8.4. Recent development
10.9. Koya Medical
10.9.1. Company presentation
10.9.2. Financial performance
10.9.3. Product Benchmarking
10.9.4. Recent development
10.10. Lohmann & Rauscher
10.10.1. Company presentation
10.10.2. Financial performance
10.10.3. Product Benchmarking
10.10.4. Recent development
10.11. Medi GmbH
10.11.1. Company presentation
10.11.2. Financial performance
10.11.3. Product Benchmarking
10.11.4. Recent development
10.12. Mego Afek ltd.
10.12.1. Company presentation
10.12.2. Financial performance
10.12.3. Product Benchmarking
10.12.4. Recent development
10.13.1. Company presentation
10.13.2. Financial performance
10.13.3. Product Benchmarking
10.13.4. Recent development
10.14.1. Company presentation
10.14.2. Financial performance
10.14.3. Product Benchmarking
10.14.4. Recent development
10.15. Smith+Neveu HERANTIS PHARMA Plc
10.15.1. Company presentation
10.15.2. Financial performance
10.15.3. Product Benchmarking
10.15.4. Recent development
10.16. Medical Touch
10.16.1. Company presentation
10.16.2. Financial performance
10.16.3. Product Benchmarking
10.16.4. Recent development
10.17. ThermoTek
10.17.1. Company presentation
10.17.2. Financial performance
10.17.3. Product Benchmarking
10.17.4. Recent development

For more information on this report, visit https://www.researchandmarkets.com/r/pbgrum

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets